25.54 USD
+0.1 (+0.39%)
Taking everything into account, XOMAO scores 5 out of 10 in our fundamental rating. XOMAO was compared to 531 industry peers in the Biotechnology industry. XOMAO has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMAO is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year XOMAO was profitable.
In the past year XOMAO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: XOMAO reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMAO reported negative operating cash flow in multiple years.
1.2 Ratios
XOMAO has a Return On Assets of 3.75%. This is amongst the best in the industry. XOMAO outperforms 90.02% of its industry peers.
Looking at the Return On Equity, with a value of 9.14%, XOMAO belongs to the top of the industry, outperforming 92.84% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.31%, XOMAO belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| ROIC | 3.31% |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 20.96%, XOMAO belongs to the best of the industry, outperforming 93.97% of the companies in the same industry.
The Operating Margin of XOMAO (20.92%) is better than 95.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.92% | ||
| PM (TTM) | 20.96% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XOMAO is destroying value.
XOMAO has more shares outstanding than it did 1 year ago.
XOMAO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for XOMAO is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -4.56, we must say that XOMAO is in the distress zone and has some risk of bankruptcy.
XOMAO has a Altman-Z score of -4.56. This is in the lower half of the industry: XOMAO underperforms 61.39% of its industry peers.
XOMAO has a Debt/Equity ratio of 0.87. This is a neutral value indicating XOMAO is somewhat dependend on debt financing.
The Debt to Equity ratio of XOMAO (0.87) is worse than 75.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.56 |
ROIC/WACC0.37
WACC8.94%
2.3 Liquidity
XOMAO has a Current Ratio of 3.91. This indicates that XOMAO is financially healthy and has no problem in meeting its short term obligations.
XOMAO has a Current ratio of 3.91. This is comparable to the rest of the industry: XOMAO outperforms 46.14% of its industry peers.
XOMAO has a Quick Ratio of 3.91. This indicates that XOMAO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.91, XOMAO is in line with its industry, outperforming 47.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 135.71% over the past year.
The Revenue has grown by 103.96% in the past year. This is a very strong growth!
Measured over the past years, XOMAO shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
3.2 Future
XOMAO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.32% yearly.
The Revenue is expected to grow by 34.85% on average over the next years. This is a very strong growth
EPS Next Y153.81%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.56%
Revenue Next 2Y43.09%
Revenue Next 3Y34.85%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 34.05 indicates a quite expensive valuation of XOMAO.
92.47% of the companies in the same industry are more expensive than XOMAO, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.34, XOMAO is valued a bit more expensive.
Based on the Price/Forward Earnings ratio of 120.57, the valuation of XOMAO can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of XOMAO indicates a rather cheap valuation: XOMAO is cheaper than 88.70% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, XOMAO is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.05 | ||
| Fwd PE | 120.57 |
4.2 Price Multiples
92.47% of the companies in the same industry are more expensive than XOMAO, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 31.01 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
XOMAO's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y45.01%
EPS Next 3Y37.32%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 8.23%, XOMAO is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 66.57, XOMAO pays a better dividend. On top of this XOMAO pays more dividend than 99.62% of the companies listed in the same industry.
XOMAO's Dividend Yield is rather good when compared to the S&P500 average which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 8.23% |
5.2 History
XOMAO has been paying a dividend for over 5 years, so it has already some track record.
XOMAO has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
5.3 Sustainability
55.43% of the earnings are spent on dividend by XOMAO. This is a bit on the high side, but may be sustainable.
DP55.43%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (12/8/2025, 8:00:02 PM)
25.54
+0.1 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.66%
Inst Owner ChangeN/A
Ins Owners1.79%
Ins Owner ChangeN/A
Market Cap316.19M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts82
Price Target58.42 (128.74%)
Short Float %0.01%
Short Ratio0.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 8.23% |
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)11.94%
PT rev (3m)13.54%
EPS NQ rev (1m)-127.67%
EPS NQ rev (3m)-4350%
EPS NY rev (1m)100.31%
EPS NY rev (3m)204.67%
Revenue NQ rev (1m)-9.59%
Revenue NQ rev (3m)-9.59%
Revenue NY rev (1m)-6.18%
Revenue NY rev (3m)-2.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.05 | ||
| Fwd PE | 120.57 | ||
| P/S | 6.71 | ||
| P/FCF | N/A | ||
| P/OCF | 57.81 | ||
| P/B | 2.93 | ||
| P/tB | 4.99 | ||
| EV/EBITDA | 31.01 |
EPS(TTM)0.75
EY2.94%
EPS(NY)0.21
Fwd EY0.83%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.73%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.22
PEG (5Y)N/A
Graham Number12.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| ROCE | 4.2% | ||
| ROIC | 3.31% | ||
| ROICexc | 4.14% | ||
| ROICexgc | 5.42% | ||
| OM | 20.92% | ||
| PM (TTM) | 20.96% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 7.77 | ||
| Cap/Depr | 880.03% | ||
| Cap/Sales | 42.84% | ||
| Interest Coverage | 0.83 | ||
| Cash Conversion | 45.03% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | -4.56 |
F-Score6
WACC8.94%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y153.81%
EPS Next 2Y45.01%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.56%
Revenue Next 2Y43.09%
Revenue Next 3Y34.85%
Revenue Next 5YN/A
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year158.48%
EBIT Next 3Y50.21%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A
XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ
What is the ChartMill fundamental rating of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?
ChartMill assigns a fundamental rating of 5 / 10 to XOMAO.
What is the valuation status of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?
ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO). This can be considered as Fairly Valued.
Can you provide the profitability details for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a profitability rating of 5 / 10.
What is the earnings growth outlook for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?
The Earnings per Share (EPS) of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is expected to grow by 153.81% in the next year.
How sustainable is the dividend of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?
The dividend rating of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 6 / 10 and the dividend payout ratio is 55.43%.